| | | CHAQ score | Poor Physical health |
|---|
| | | = 0 | > 0 | CHAQ score > 0 |
|---|
Other outcome measures | Na | n (%) | n (%) | OR (95% CI) crude | OR (95% CI) adjustedb |
|---|
VAS painc |
= 0 | 82 | 63 (76.8) | 19 (23.2) | 1.0 (ref.) | 1.0 (ref.) |
> 0 | 139 | 30 (21.6) | 109 (78.4) | 12.0 (6.3, 23.1) | 14.1 (6.8, 29.2) |
PatGA VASd |
= 0 | 61 | 50 (82.0) | 11 (18.0) | 1.0 (ref.) | 1.0 (ref.) |
> 0 | 160 | 43 (26.9) | 117 (73.1) | 12.4 (5.9, 25.9) | 14.0 (6.2, 31.6) |
Morning stiffness |
< 15 min | 166 | 85 (51.2) | 81 (48.8) | 1.0 (ref.) | 1.0 (ref.) |
≥ 15 min | 49 | 7 (14.3) | 42 (85.7) | 6.3 (2.7, 14.8) | 7.0 (2.9, 16.9) |
CHQ PhS |
≥ 40 | 165 | 89 (53.9) | 76 (46.1) | 1.0 (ref.) | 1.0 (ref.) |
< 40 | 53 | 3 (5.7) | 50 (94.3) | 19.5 (5.9, 65.1) | 19.0 (5.6, 64.1) |
CHQ PsS |
≥ 40 | 199 | 90 (45.2) | 109 (54.8) | 1.0 (ref.) | 1.0 (ref.) |
< 40 | 19 | 2 (10.5) | 17 (89.5) | 7.0 (1.6, 31.2) | 8.1 (1.8, 37.3) |
PhysGAe |
= 0 | 146 | 80 (54.8) | 66 (45.2) | 1.0 (ref.) | 1.0 (ref.) |
> 0 | 75 | 13 (17.3) | 62 (82.7) | 5.8 (2.9, 11.4) | 6.2 (3.1, 12.6) |
Disease statusf |
Rem. off med. | 29 | 25 (86.2) | 4 (13.8) | 1.0 (ref.) | 1.0 (ref.) |
Inactive | 106 | 55 (51.9) | 51 (48.1) | 5.8 (1.9, 17.8) | 5.4 (1.7, 17.3) |
Active | 86 | 13 (15.1) | 73 (84.9) | 35.1 (10.5, 117.6) | 36.3 (10.3, 128.1) |
Medication ongoingg |
No DMARDs | 77 | 43 (55.8) | 34 (44.2) | 1.0 (ref) | 1.0 (ref) |
DMARDs | 144 | 50 (34.7) | 94 (65.3) | 2.4 (1.4, 4.2) | 2.2 (1.2, 3.9) |
Medication everg |
No DMARDs | 55 | 30 (54.5) | 25 (45.5) | 1.0 (ref) | 1.0 (ref) |
DMARDs | 166 | 63 (38.0) | 103 (62.0) | 2.0 (1.1, 3.6) | 1.9 (1, 3.6) |
JIA categoryh |
Oligo. persistent | 76 | 40 (52.6) | 36 (47.4) | 1.0 (ref) | 1.0 (ref) |
Other | 145 | 53 (36.6) | 92 (63.5) | 1.9 (1.1, 3.4) | 2.0 (1.1, 3.6) |
- JIA Juvenile idiopathic arthritis, N Number, CHAQ Childhood Health Assessment Questionnaire, OR Odds ratio, CI Confidence interval, VAS Visual analogue scale, ref. reference, PatGA Patient Global Assessment of disease impact on well-being, CHQ Child Health Questionnaire, PhS Physical Summary Score, PsS Psychosocial Summary Score, PhysGA Physician's global assessment of disease activity, Rem. off med. Remission off medication, DMARDs disease modifying anti-rheumatic drugs, including synthetic (methotrexate, hydroxychloroquine, cyclosporine, mycophenolate mofetil) and/or biologic DMARDs (etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab, rituximab). Oligo. Oligoarticular
- aN assessed for each variable, excluding missing/unknown values. Total participants, N = 221
- bAdjusted for sex, age, disease duration, and Iso-BMI
- cSelf-reported disease-related pain measured on a 21-numbered circle VAS pain (0 = no pain, 10 = maximum pain)
- dAssessed by the patient/parent on a 21-numbered circle VAS (0 = very well, 10 = very poor)
- eAssessed by the physician on a 21-numbered circle VAS (0 = inactive, 10 = maximal activity)
- fDisease status according to [14] and [15]: Rem. off med. for ≥ 12 months. Inactive disease = inactive disease on medication < 6 months or off medication < 12 months, or remission on medication (inactive disease on medication for > 6 months). Active disease = flare or continuous active disease
- gOngoing refers to ongoing medication for arthritis or uveitis at the study visit. Ever refers to medication ever used for arthritis or uveitis during the disease course, including ongoing medication. Registered medication was dichotomized into No DMARDs and DMARDs
- hCategories defined according to the International League of Association for Rheumatology (ILAR) classification criteria and dichotomized into oligoarticular persistent JIA versus all other categories
